

## RADIATION ONCOLOGY QUALITY ASSURANCE COMMITTEE

CHELSEA HOTEL, TORONTO, ON  
ROOM: CARLYLE B

FRIDAY APRIL 25TH, 2025 1:00 PM – 4:00 PM

RADIATION ONCOLOGIST CO-CHAIR: ALAN NICHOL  
MEDICAL PHYSICIST CO-CHAIR: OREST OSTAPIAK

### CME Credits:

*Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.*

### Learning Objectives:

- To review CCTG led trials testing radiotherapy interventions including the quality assurance infrastructure.
- To identify best practices and quality initiatives in radiotherapy delivery as they relate to clinical trial conduct.
- To provide input and guidance for the CCTG generic protocol regarding radiotherapy administration and quality assurance.

<b>1:00 pm</b>	<b>Welcome</b>	<b>A. Nichol</b>
<b>1:05 pm</b>	<b><u>CCTG Approved Trials Recently Activated</u></b>	
	Androgen Suppression Combined with Elective Nodal Irradiation and Dose Escalated Prostate Treatment: A Non-Inferiority, Phase III Randomized Controlled Trial of Stereotactic Body Radiation Therapy versus Brachytherapy Boost (ASCENDE-SBRT). <b>PR.24</b>	<b>A. Loblaw</b>
	Optimizing Head and Neck Tumour And Symptom Control in Patients Unable to Tolerate Curative Intent RT: A Phase III Trial Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study). <b>HN.13</b>	<b>I. Karam</b>
	A Randomized Phase 3 Trial Comparing Stereotactic Body Radiotherapy to Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases. <b>SC.29</b>	<b>A. Sahgal</b>
	Consolidative Use Of Radiotherapy To Block (CURB2) Oligoprogression In Patients With Metastatic Non-Small-Cell Lung Cancer – A Randomized Phase 3 Trial. <b>BR.38</b>	<b>A. Sun</b>

**Meeting Adjourned**



Accrual Updates for CCTG Ongoing Trials Previously Presented:

**PR.19:** Phase II randomized study comparing HDR vs LDR monotherapy in localized prostate cancer.

Current Accrual: **335/335 Target accrual met**

**PR.20:** Phase 3 Trial of Local Ablative Therapy or Not for Hormone Sensitive Oligometastatic Prostate Cancer.

Current Accrual: **410/410 Target accrual met**

**MA.39:** TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer.

Current Accrual: **1759/2140**

**CE.7:** A Phase III Trial of Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases.

Current Accrual: **156/206**

**HN.9:** Randomized Phase II Study of Cisplatin + RT vs Durvalumab + RT followed by Maintenance Durvalumab vs Durvalumab plus RT followed by Maintenance Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Ca (LA-OSCC).

Current Accrual: **129/180 (accrual closed)**

**HN.11:** SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharynx Cancer (SELECT): A Phase III Randomized Controlled Trial.

Current Accrual: **88/510**

